PWP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PWP is not a good buy right now. The stock is technically extended (RSI very overbought) and close to near-term resistance, while fundamentals just printed steep YoY declines and hedge funds have been selling aggressively. With earnings (QDec 2025) coming on 2026-02-06 pre-market, the risk/reward is skewed against chasing at current levels for an impatient buyer.
Trend is bullish but stretched: SMA_5 > SMA_20 > SMA_200 confirms an uptrend, and MACD histogram is positive (0.19) but contracting, suggesting upside momentum is fading. RSI_6 at 82.39 flags an overbought condition, which often precedes pullbacks or sideways consolidation. Price (22.37) is above the pivot (21.679) and approaching resistance R1 (22.691); a near-term breakout would need strong follow-through, otherwise mean-reversion risk is elevated. Probabilistic pattern read: +1.29% next day (40% chance), -3.21% next week, +4.69% next month—near-term skew is not compelling for an immediate entry.
Intellectia Proprietary Trading Signals:
could re-rate the stock if advisory activity/revenue surprises to the upside.
leans bullish, suggesting some investors are positioned for upside.
with MACD momentum contracting increases near-term pullback risk, especially near resistance (R1 22.691).
Latest reported quarter: 2025/Q3. Results weakened materially YoY: revenue 164.645M (-40.83% YoY), net income 6.004M (-63.32% YoY), EPS 0.08 (-66.67% YoY). This is a clear deceleration/drawdown in earnings power versus last year, which makes the current price strength more vulnerable if the next earnings print doesn’t show a rebound.
Analyst trend (latest item): On 2025-11-10, Keefe Bruyette lowered the price target to $19 from $21 and kept a Market Perform rating. That’s a negative revision, and the lowered target sits below the current price (22.37), implying limited upside in the analyst’s base case. Wall Street pros/cons view based on available data: Pros—still viewed as broadly ‘perform’ (not an outright downgrade to underperform) and technical trend is up. Cons—price target cut and target below spot, plus recent fundamentals are sharply down YoY, which can justify caution at elevated prices. Influential buying/selling: no recent congress trading data; insiders are neutral; hedge funds are net sellers (notable negative).
